- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2011 (2011), Article ID 903097, 8 pages
Methotrexate Toxicity in Growing Long Bones of Young Rats: A Model for Studying Cancer Chemotherapy-Induced Bone Growth Defects in Children
1Sansom Institute for Health Research, and School of Pharmacy and Medical Sciences, University of South Australia, City East Campus, GPO Box 2471, Adelaide, SA 5001, Australia
2Discipline of Paediatrics, University of Adelaide, Adelaide, SA 5005, Australia
3Discipline of Physiology, University of Adelaide, Adelaide, SA 5005, Australia
Received 10 September 2010; Accepted 21 January 2011
Academic Editor: Andrea Vecchione
Copyright © 2011 Chiaming Fan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- H. M. Kronenberg, “Developmental regulation of the growth plate,” Nature, vol. 423, no. 6937, pp. 332–336, 2003.
- D. B. Pateder, R. A. Eliseev, R. J. O'Keefe et al., “The role of autocrine growth factors in radiation damage to the epiphyseal growth plate,” Radiation Research, vol. 155, no. 6, pp. 847–857, 2001.
- H. Robson, “Bone growth mechanisms and the effects of cytotoxic drugs,” Archives of Disease in Childhood, vol. 81, no. 4, pp. 360–364, 1999.
- B. C. J. van der Eerden, M. Karperien, and J. M. Wit, “Systemic and local regulation of the growth plate,” Endocrine Reviews, vol. 24, no. 6, pp. 782–801, 2003.
- J. Wang, J. Zhou, C. M. Cheng, J. J. Kopchick, and C. A. Bondy, “Evidence supporting dual, IGF-I-independent and IGF-I-dependent, roles for GH in promoting longitudinal bone growth,” Journal of Endocrinology, vol. 180, no. 2, pp. 247–255, 2004.
- O. Nilsson, D. Chrysis, O. Pajulo et al., “Localization of estrogen receptors-α and -β and androgen receptor in the human growth plate at different pubertal stages,” Journal of Endocrinology, vol. 177, no. 2, pp. 319–326, 2003.
- J. Ophoff, K. Venken, F. Callewaert, S. Boonen, R. Bouillon, and D. Vanderschueren, “Sex steroids during bone growth: a comparative study between mouse models for hypogonadal and senile osteoporosis,” Osteoporosis International, vol. 20, no. 10, pp. 1749–1757, 2009.
- K. Venken, F. Callewaert, S. Boonen, and D. Vanderschueren, “Sex hormones, their receptors and bone health,” Osteoporosis International, vol. 19, no. 11, pp. 1517–1525, 2008.
- C. J. Xian, “Roles of epidermal growth factor family in the regulation of postnatal somatic growth,” Endocrine Reviews, vol. 28, no. 3, pp. 284–296, 2007.
- D. Chen, M. Zhao, and G. R. Mundy, “Bone morphogenetic proteins,” Growth Factors, vol. 22, no. 4, pp. 233–241, 2004.
- T. A. Linkhart, S. Mohan, and D. J. Baylink, “Growth factors for bone growth and repair: IGF, TGFβ and BMP,” Bone, vol. 19, no. 1, pp. 1S–12S, 1996.
- P. Ammann, S. Bourrin, J. P. Bonjour, J. M. Meyer, and R. Rizzoli, “Protein undernutrition-induced bone loss is associated with decreased IGF-I levels and estrogen deficiency,” Journal of Bone and Mineral Research, vol. 15, no. 4, pp. 683–690, 2000.
- A. L. Bueno and M. A. Czepielewski, “The importance for growth of dietary intake of calcium and vitamin D,” Jornal de Pediatria, vol. 84, no. 5, pp. 386–394, 2008.
- C. C. Johnston, J. Z. Miller, C. W. Slemenda et al., “Calcium supplementation and increases in bone mineral density in children,” The New England Journal of Medicine, vol. 327, no. 2, pp. 82–87, 1992.
- C. H. Pui, L. L. Robison, and A. T. Look, “Acute lymphoblastic leukaemia,” The Lancet, vol. 371, no. 9617, pp. 1030–1043, 2008.
- M. Abromowitch, J. Ochs, C. H. Pui, D. Fairclough, S. B. Murphy, and G. K. Rivera, “Efficacy of high-dose methotrexate in childhood acute lymphocytic leukemia: analysis by contemporary risk classifications,” Blood, vol. 71, no. 4, pp. 866–869, 1988.
- N. J. Minaur, C. Jefferiss, A. K. Bhalla, and J. N. Beresford, “Methotrexate in the treatment of rheumatoid arthritis. I. In vitro effects on cells of the osteoblast lineage,” Rheumatology, vol. 41, no. 7, pp. 735–740, 2002.
- B. N. Cronstein, “Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis,” Pharmacological Reviews, vol. 57, no. 2, pp. 163–172, 2005.
- N. Boukhettala, J. Leblond, S. Claeyssens et al., “Methotrexate induces intestinal mucositis and alters gut protein metabolism independently of reduced food intake,” American Journal of Physiology, vol. 296, no. 1, pp. E182–E190, 2009.
- M. Sosin and S. Handa, “Lesson of the week: low dose methotrexate and bone marrow suppression,” British Medical Journal, vol. 326, no. 7383, pp. 266–267, 2003.
- W. Högler, G. Wehl, T. van Staa, B. Meister, A. Klein-Franke, and G. Kropshofer, “Incidence of skeletal complications during treatment of childhood acute lymphoblastic leukemia: comparison of fracture risk with the general practice research database,” Pediatric Blood and Cancer, vol. 48, no. 1, pp. 21–27, 2007.
- I. M. van der Sluis, M. M. van den Heuvel-Eibrink, K. Hählen, E. P. Krenning, and S. M. P. F. De Muinck Keizer-Schrama, “Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia,” Journal of Pediatrics, vol. 141, no. 2, pp. 204–210, 2002.
- P. M. Crofton, S. F. Ahmed, J. C. Wade et al., “Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 9, pp. 3121–3129, 1998.
- J. M. Halton, S. A. Atkinson, L. Fraher et al., “Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia,” Journal of Bone and Mineral Research, vol. 11, no. 11, pp. 1774–1783, 1996.
- K. Mandel, S. Atkinson, R. D. Barr, and P. Pencharz, “Skeletal morbidity in childhood acute lymphoblastic leukemia,” Journal of Clinical Oncology, vol. 22, no. 7, pp. 1215–1221, 2004.
- J. M. Halton, S. A. Atkinson, and R. D. Barr, “Growth and body composition in response to chemotherapy in children with acute lymphoblastic leukemia,” International Journal of Cancer, vol. 78, no. 11, pp. 81–84, 1998.
- M. B. Viana and M. I. Vilela, “Height deficit during and many years after treatment for acute lymphoblastic leukemia in children: a review,” Pediatric Blood and Cancer, vol. 50, no. 2, pp. 509–516, 2008.
- B. L. van Leeuwen, W. A. Kamps, R. M. Hartel, R. P. H. Veth, W. J. Sluiter, and H. J. Hoekstra, “Effect of single chemotherapeutic agents on the growing skeleton of the rat,” Annals of Oncology, vol. 11, no. 9, pp. 1121–1126, 2000.
- S. Walsh, G. R. Jordan, C. Jefferiss, K. Stewart, and J. N. Beresford, “High concentrations of dexamethasone suppress the proliferation but not the differentiation or further maturation of human osteoblast precursors in vitro: relevance to glucocorticoid-induced osteoporosis,” Rheumatology, vol. 40, no. 1, pp. 74–83, 2001.
- W. S. Jee and W. Yao, “Overview: animal models of osteopenia and osteoporosis,” Journal of Musculoskeletal and Neuronal Interactions, vol. 1, no. 3, pp. 193–207, 2001.
- M. B. Leonard, “Glucocorticoid-induced osteoporosis in children: impact of the underlying disease,” Pediatrics, vol. 119, no. 2, pp. S166–S174, 2007.
- H. Robson, E. Anderson, O. B. Eden, O. Isaksson, and S. Shalet, “Chemotherapeutic agents used in the treatment of childhood malignancies have direct effects on growth plate chondrocyte proliferation,” Journal of Endocrinology, vol. 157, no. 2, pp. 225–235, 1998.
- B. L. van Leeuwen, R. M. Hartel, H. W. B. Jansen, W. A. Kamps, and H. J. Hoekstra, “The effect of chemotherapy on the morphology of the growth plate and metaphysis of the growing skeleton,” European Journal of Surgical Oncology, vol. 29, no. 1, pp. 49–58, 2003.
- C. Fan, J. C. Cool, M. A. Scherer et al., “Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment,” Bone, vol. 44, no. 1, pp. 61–70, 2009.
- C. J. Xian, J. C. Cool, M. A. Scherer et al., “Cellular mechanisms for methotrexate chemotherapy-induced bone growth defects,” Bone, vol. 41, no. 5, pp. 842–850, 2007.
- C. J. Xian, J. C. Cool, M. A. Scherer, C. Fan, and B. K. Foster, “Folinic acid attenuates methotrexate chemotherapy-induced damages on bone growth mechanisms and pools of bone marrow stromal cells,” Journal of Cellular Physiology, vol. 214, no. 3, pp. 777–785, 2008.
- O. S. Nilsson, F. C. H. Bauer, L. A. Brostrom, and U. Nilsonne, “Effect of the antineoplastic agent methotrexate on experimental heterotopic new bone formation in rats,” Cancer Research, vol. 44, no. 4, pp. 1653–1656, 1984.
- D. L. Wheeler, R. A. Vander Griend, T. J. Wronski, G. J. Miller, E. E. Keith, and J. E. Graves, “The short- and long-term effects of methotrexate on the rat skeleton,” Bone, vol. 16, no. 2, pp. 215–221, 1995.
- K. P. May, D. Mercill, M. T. McDermott, and S. G. West, “The effect of methotrexate on mouse bone cells in culture,” Arthritis and Rheumatism, vol. 39, no. 3, pp. 489–494, 1996.
- D. Benayahu, “The osteogenic compartment of bone marrow: cell biology and clinical application,” Hematology, vol. 4, no. 5, pp. 427–435, 2000.
- A. Banfi, M. Podestà, L. Fazzuoli et al., “High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia,” Cancer, vol. 92, no. 9, pp. 2419–2428, 2001.
- J. H. Davies, B. A. J. Evans, M. E. M. Jenney, and J. W. Gregory, “In vitro effects of combination chemotherapy on osteoblasts: implications for osteopenia in childhood malignancy,” Bone, vol. 31, no. 2, pp. 319–326, 2002.
- J. Li, H. K. W. Law, L. L. Yu, and G. C. F. Chan, “Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents,” British Journal of Haematology, vol. 127, no. 3, pp. 326–334, 2004.
- L. P. Mueller, J. Luetzkendorf, T. Mueller, K. Reichelt, H. Simon, and H. J. Schmoll, “Presence of mesenchymal stem cells in human bone marrow after exposure to chemotherapy: evidence of resistance to apoptosis induction,” Stem Cells, vol. 24, no. 12, pp. 2753–2765, 2006.
- S. P. Hauser, K. B. Udupa, and D. A. Lipschitz, “Murine marrow stromal response to myelotoxic agents in vitro,” British Journal of Haematology, vol. 95, no. 4, pp. 596–604, 1996.
- C. N. Bennett, K. A. Longo, W. S. Wright et al., “Regulation of osteoblastogenesis and bone mass by Wnt10b,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 9, pp. 3324–3329, 2005.
- C. E. Macsai, B. K. Foster, and C. J. Xian, “Roles of Wnt signalling in bone growth, remodelling, skeletal disorders and fracture repair,” Journal of Cellular Physiology, vol. 215, no. 3, pp. 578–587, 2008.
- K. R. Georgiou, B. K. Foster, and C. J. Xian, “Damage and recovery of the bone marrow microenvironment induced by cancer chemotherapy—potential regulatory role of chemokine CXCL12/receptor CXCR4 signalling,” Current Molecular Medicine, vol. 10, no. 5, pp. 440–453, 2010.
- M. Nesbit, W. Krivit, R. Heyn, and H. Sharp, “Acute and chronic effects of methotrexate on hepatic, pulmonary, and skeletal systems,” Cancer, vol. 37, supplement 2, pp. 1048–1057, 1976.
- K. P. May, S. G. West, M. T. McDermott, and W. E. Huffer, “The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats,” Arthritis and Rheumatism, vol. 37, no. 2, pp. 201–206, 1994.
- G. E. Friedlaender, R. B. Tross, and A. C. Doganis, “Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model,” Journal of Bone and Joint Surgery. American, vol. 66, no. 4, pp. 602–607, 1984.
- H. Hayashi, K. I. Nakahama, T. Sato et al., “The role of Mac-1 (CD11b/CD18) in osteoclast differentiation induced by receptor activator of nuclear factor-κB ligand,” FEBS Letters, vol. 582, no. 21-22, pp. 3243–3248, 2008.
- M. Darst, M. Al-Hassani, T. Li et al., “Augmentation of chemotherapy-induced cytokine production by expression of the platelet-activating factor receptor in a human epithelial carcinoma cell line,” Journal of Immunology, vol. 172, no. 10, pp. 6330–6335, 2004.
- W. J. Boyle, W. S. Simonet, and D. L. Lacey, “Osteoclast differentiation and activation,” Nature, vol. 423, no. 6937, pp. 337–342, 2003.
- E. M. Dennisona, C. Coopera, and Z. A. Colea, “Early development and osteoporosis and bone health,” Journal of Developmental Origins of Health and Disease, vol. 1, pp. 142–149, 2010.